PRMEPrime Medicine, Inc.

$771M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$40M

Net Income

-$39M

EPS (Diluted)

$-0.44

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$42M

Free Cash Flow

-$44M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$317M

Total Liabilities

$38M

Stockholders' Equity

$279M

Cash & Equivalents

$133M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$40M	-$20M	-101.2%
Net Income	-$39M	-$24M	-65.3%

PRME Q1 2023 Earnings — Prime Medicine, Inc. Revenue & Financial Results | Market Cap Arena